Merck KGaA's tepotinib meets in two Phase Ib/II trials for advanced HCC

Merck KGaA (Xetra:MRK) said once-daily oral tepotinib (MSC2156119J) as first- and second-line treatment each met the primary endpoints in the Phase II portions of two open-label Phase Ib/II trials to treat advanced c-Met

Read the full 330 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE